1.00

14.35% -0.1675

Brainstorm Cell Therapeutics Inc (BCLI)

Overview News Price History Option Chain Financials Why BCLI Down? Discussions Forecast Stock Split

Brainstorm Cell Therapeutics Inc stock is traded at $1.00, with a volume of 17,436. It is down -14.35% in the last 24 hours and down -14.35% over the past month. BRAINSTORM CELL THERAPUTC

Previous Close:

$1.1675

Open:

$0.94301

24h Volume:

17,436

Relative Volume:

16.03

Market Cap:

$N/A

Revenue:

Net Income/Loss:

$-9.57M

P/E Ratio:

-1.0621

EPS:

-0.9415

Net Cash Flow:

$-6.66M

1W Performance:

-14.35%

1M Performance:

-14.35%

6M Performance:

+87.27%

1Y Performance:

-87.10%

1-Day Range:

$0.922

$1.08

1-Week Range:

$0.922

$1.08

52-Week Range:

$0.534

$1.19

Brainstorm Cell Therapeutics Inc Stock (BCLI) Company Profile

Name

Brainstorm Cell Therapeutics Inc

Sector

Healthcare (1068)

Industry

Biotechnology (594)

Phone

Address

Employee

Twitter

Next Earnings Date

2024-11-05

Latest SEC Filings

BCLI's Discussions on Twitter

Compare BCLI vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BCLI Brainstorm Cell Therapeutics Inc	1.00	0	0	-9.57M	-6.66M	-0.9415
VRTX Vertex Pharmaceuticals Inc	506.74	133.37B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	734.81	81.13B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	188.94	79.40B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	936.00	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	205.89	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Brainstorm Cell Therapeutics Inc Stock (BCLI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-04-21	Upgrade	Maxim Group	Hold → Buy
Nov-17-20	Downgrade	Maxim Group	Buy → Hold
Dec-19-16	Reiterated	Maxim Group	Buy
Dec-22-15	Reiterated	Maxim Group	Buy

Brainstorm Cell Therapeutics Inc Stock (BCLI) Latest News

Sep 18, 2026

Brainstorm Cell Therapeutics Stock Price Forecast. Should You Buy BCLI? - StockInvest.us

Sep 18, 2026

Aug 24, 2026

BrainStorm Executive Leadership to Participate in DUPHAT 2026; Executive Chairman Peter J. Pitts Invited to Deliver Two Keynote Addresses and Moderate Panel Sessions - Yahoo Finance

Aug 24, 2026

Aug 21, 2026

Brainstorm Cell Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Pitts Peter Joe - Moomoo

Aug 21, 2026

Aug 14, 2026

BrainStorm Cash Drops to $0.2 Million, Raising Going-Concern Risk - Minichart

Aug 14, 2026

Brainstorm Cell Therapeutics (BCLI) posts loss and warns on going concern - Stock Titan

Aug 14, 2026

BCLI: Phase 3b ALS trial preparations advance as net loss widens and new capital is secured - TradingView

Aug 14, 2026

BrainStorm Posts $3.9 Million Second-Quarter Net Loss as NurOwn Trial Preparations Continue - Quiver Quantitative

Aug 14, 2026

Brainstorm Cell Therapeutics | 8-K: BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update - Moomoo

Aug 14, 2026

BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update - PR Newswire

Aug 14, 2026

Aug 04, 2026

Lunai Bioworks signs collaboration with BrainStorm Therapeutics By Investing.com - Investing.com South Africa

Aug 04, 2026

Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027 - PR Newswire

Aug 04, 2026

Aug 01, 2026

Brainstorm Appoints Former FDA Associate Comm - Moomoo

Aug 01, 2026

Jul 30, 2026

BrainStorm Cell Reshapes Leadership to Advance NurOwn Trial - TipRanks

Jul 30, 2026

Jul 28, 2026

Form 4 Brainstorm Cell Therapeutics Inc For: 28 July By Investing.com - Investing.com Nigeria

Jul 28, 2026

BrainStorm Cell (BCLI) grants 100,000 RSUs to director Frenkel - Stock Titan

Jul 28, 2026

Brainstorm Cell Therapeutics Inc. Announces Executive and Board Changes - marketscreener.com

Jul 28, 2026

BrainStorm names ex-FDA official Pitts as executive chairman By Investing.com - Investing.com Canada

Jul 28, 2026

BrainStorm's ALS Trial Set to Launch Under First-Ever Special Protocol Assessment - Stock Titan

Jul 28, 2026

BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman - Prime Publishers, Inc.

Jul 28, 2026

Jul 15, 2026

CYVNY Stock Price and Chart — OTC:CYVNY - TradingView

Jul 15, 2026

Jul 13, 2026

Peter Joe Pitts Net Worth (2026) - GuruFocus

Jul 13, 2026

Jul 09, 2026

Price to earnings forward of BrainStorm Cell Therapeutics Inc. – OTC:BCLI - TradingView

Jul 09, 2026

Jul 08, 2026

Price to earnings forward of Brainstorm Cell Therapeutics Inc. – SWB:GHD - TradingView

Jul 08, 2026

Jul 02, 2026

Brainstorm Cell Therapeutics (BCLI) Status Update Summary - Quartr

Jul 02, 2026

Jul 01, 2026

Amyotrophic Lateral Sclerosis Market Gains Momentum with Expanding Pipeline and Investment Potential by 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK - Barchart.com

Jul 01, 2026

Jun 27, 2026

Brainstorm Cell Therapeutics Inc. Actuals & Estimates (OTC:BCLI) - TradingView

Jun 27, 2026

Jun 24, 2026